Revenue Recognition (Tables)

9 Months Ended

Sep. 30, 2018

Revenue From Contract With Customer [Abstract]

Schedule of Company's Revenue for Reportable Segment by Country Based on Locations of Customer

Disaggregation of revenue

The following represents the Company’s revenue for its reportable segment by country, based on the locations of the customer.

	For the Three Months Ended September 30, 2018
	(In Thousands)
	Oncology Innovation Platform		Global Supply Chain Platform		Commercial Platform		Consolidated Total
United States	$	—	$	2,244	$	7,315	$	9,559
Spain		5,000		—		—		5,000
India		—		258		—		258
Austria		—		2,227		—		2,227
China		117		189		—		306
Other foreign countries		—		1,077		—		1,077
Total revenue	$	5,117	$	5,996	$	7,315	$	18,428

	For the Three Months Ended September 30, 2017
	(In Thousands)
	Oncology Innovation Platform		Global Supply Chain Platform		Commercial Platform		Consolidated Total
United States	$	—	$	736	$	7,378	$	8,114
India		—		3,015		—		3,015
Austria		—		964		—		964
China		205		833		—		1,038
Other foreign countries		—		863		—		863
Total revenue	$	205	$	6,411	$	7,378	$	13,994

	For the Nine Months Ended September 30, 2018
	(In Thousands)
	Oncology Innovation Platform		Global Supply Chain Platform		Commercial Platform		Consolidated Total
United States	$	—	$	4,399	$	23,006	$	27,405
Spain		30,000		—		—		30,000
India		—		1,701		—		1,701
Austria		—		5,102		—		5,102
China		532		1,385		—		1,917
Other foreign countries		—		1,704		—		1,704
Total revenue	$	30,532	$	14,291	$	23,006	$	67,829

	For the Nine Months Ended September 30, 2017
	(In Thousands)
	Oncology Innovation Platform		Global Supply Chain Platform		Commercial Platform		Consolidated Total
United States	$	—	$	1,781	$	9,274	$	11,055
India		—		5,275		—		5,275
Austria		—		2,682		—		2,682
China		708		1,058		—		1,766
Other foreign countries		500		1,892		—		2,392
Total revenue	$	1,208	$	12,688	$	9,274	$	23,170

Summary of Receivables and Contract Liabilities From Contracts with Customers

The following table provides information about receivables and contract liabilities from contracts with customers. The Company has not recorded any contract assets from contracts with customers.

	September 30, 2018			December 31, 2017
	(In Thousands)
Accounts receivable, gross	$	20,252		$	12,263
Chargebacks and other deductions		(13,154	)		(3,711	)
Allowance for doubtful accounts		(27	)		(84	)
Accounts receivable, net	$	7,071		$	8,468
Deferred revenue	$	364		$	1,202
Total contract liabilities	$	364		$	1,202

Summary of Accounts Receivable Balances by Reportable Segments

The following tables illustrate accounts receivable balances by reportable segments.

	September 30, 2018
	(In Thousands)
	Oncology Innovation Platform		Global Supply Chain Platform			Commercial Platform			Consolidated Total
Accounts receivable, gross	$	9	$	3,369		$	16,874		$	20,252
Chargebacks and other deductions		—		—			(13,154	)		(13,154	)
Allowance for doubtful accounts		—		(27	)		—			(27	)
Accounts receivable, net	$	9	$	3,342		$	3,720		$	7,071

	December 31, 2017
	(In Thousands)
	Oncology Innovation Platform		Global Supply Chain Platform			Commercial Platform			Consolidated Total
Accounts receivable, gross	$	49	$	4,553		$	7,661		$	12,263
Allowance for doubtful accounts, chargebacks, and    other deductions		—		(84	)		(3,711	)		(3,795	)
Accounts receivable, net	$	49	$	4,469		$	3,950		$	8,468